Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies within the biotechnology and pharmaceutical industries. The company excels in innovative automation and comprehensive biorepository services, facilitating faster drug discovery while ensuring adherence to stringent regulatory standards. With a forward-looking strategy that leverages advanced storage technologies and strategic partnerships, Azenta is uniquely positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to pioneering scientific research through sophisticated innovations underscores its potential appeal to institutional investors seeking exposure in the dynamic life sciences sector.
| Revenue (TTM) | $613.81M |
| Gross Profit (TTM) | $270.37M |
| EBITDA | $33.01M |
| Operating Margin | -2.27% |
| Return on Equity | -7.04% |
| Return on Assets | -0.73% |
| Revenue/Share (TTM) | $13.41 |
| Book Value | $34.51 |
| Price-to-Book | 0.97 |
| Price-to-Sales (TTM) | 2.40 |
| EV/Revenue | 1.94 |
| EV/EBITDA | 36.16 |
| Quarterly Earnings Growth (YoY) | 8778.00% |
| Quarterly Revenue Growth (YoY) | 12.00% |
| Shares Outstanding | $43.81M |
| Float | $38.38M |
| % Insiders | 1.05% |
| % Institutions | 117.29% |
Volatility is currently contracting
AZTA went down for a long time, resulting in a multi-year low in May 2026, but the stock has rallied higher since then. While the stock has doubled in value, there is a chart that suggests to be wary of the rally because it could unwind itself in the near future. The current financial model from AZTA makes a case for being long, but that depends on whether AZTA can hit the targets laid out.
Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript
Azenta NASDAQ: AZTA reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued unevenness in capital equipment markets.
BURLINGTON, Mass., Aug. 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2026.
BURLINGTON, Mass., July 22, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2026 earnings which ended on June 30, 2026, on Tuesday, August 4, 2026, after the market closes.
BURLINGTON, Mass., July 8, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the completion of the previously disclosed sale of its B Medical Systems business to Thelema S.
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. ("Azenta" or the "Company") (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026 -- then cut both targets three months later after recording a $149 million goodwill impairment. NEW YORK, May 27, 2026 /PRNewswire/ -- Shareholders who purchased Azenta, Inc. (NASDAQ: AZTA) stock lost significant value after the Company slashed its FY 2026 guidance on May 5, 2026 -- reversing projections it had publicly reaffirmed just three months earlier.
New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) ("Azenta, Inc.") concerning potential violations of the federal securities laws. On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for continued success" and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on AZTA and any ticker you trade — then tracks every position and per-strategy win rate.
